Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
BioSenic Appoints Lieven Huysse, MD, as Chief Medical Officer (CMO)
BioSenic, the company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces […]
Wyss Center Geneva Appoints Erwin Böttinger as New Chief Executive Officer
The Executive Board of the Wyss Center for Bio and Neuroengineering, a non-profit research center, […]
XNK Receives EU Tissue Establishment Certificate
XNK Therapeutics today announced that it has been approved as an EU Tissue Establishment. This […]
Orexo Shares New Timeline for the High-Dose Rescue Medication for Opioid Overdose, OX124
Orexo today announces the expected US launch of OX124, a high-dose rescue medication for opioid overdose, […]
SynAct Pharma Appoints Torbjørn Bjerke as New CEO
SynAct Pharma has announced the appointment of the company’s current Chairman Torbjørn Bjerke MD, as […]
NHS Hits Milestone of 200 Children with Hepatitis C Treated in Bid to Stamp Out Virus
Two hundred children in England have now received life-saving treatment for hepatitis C as part […]
Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis
Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients […]
NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business
NEC Corporation and NOI announced that NOI will be realigned as a subsidiary of NEC […]
Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions
Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and […]
Sensorion Appoints Khalil Barrage as Interim Chairman of the Board
Sensorion, a pioneering clinical-stage biotechnology company that specializes in gene therapies in the ear, announces […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more